Cytokines as Potential Therapeutic Targets and their Role in the Diagnosis and
Prediction of Cancers

Ikenna      Uchendu; Angelina      Zhilenkova; Yuliya      Pirogova; Maria      Basova; Leonid      Bagmet; Iana      Kohanovskaia; Yvan      Ngaha; Obinna      Ikebunwa; Marina      Sekacheva
Abstract

The death rate from cancer is declining as a result of earlier identification and more advanced treatments. Nevertheless, a number of unfavourable adverse effects, including prolonged, long-lasting inflammation and reduced immune function, usually coexist with anti-cancer therapies and lead to a general decline in quality of life. Improvements in standardized comprehensive therapy and early identification of a variety of aggressive tumors remain the main objectives of cancer research. Tumor markers in those with cancer are tumor- associated proteins that are clinically significant. Even while several tumor markers are routinely used, they don't always provide reliable diagnostic information. Serum cytokines are promising markers of tumor stage, prognosis, and responsiveness to therapy. In fact, several cytokines are currently proposed as potential biomarkers in a variety of cancers. It has actually been proposed that the study of circulatory cytokines together with biomarkers that are particular to cancer can enhance and accelerate cancer diagnosis and prediction, particularly via blood samples that require minimal to the absence of invasion. The purpose of this review was to critically examine relevant primary research literature in order to elucidate the role and importance of a few identified serum cytokines as prospective therapeutic targets in oncological diseases.
[1]
Marelli G, Sica A, Vannucci L, Allavena P. Inflammation as target in cancer therapy. Curr Opin Pharmacol  2017; 35: 57-65.
 [http://dx.doi.org/10.1016/j.coph.2017.05.007] [PMID: 28618326]

[2]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin  2020; 70(1): 7-30.
 [http://dx.doi.org/10.3322/caac.21590] [PMID: 31912902]

[3]
Hojman P. Exercise protects from cancer through regulation of immune function and inflammation. Biochem Soc Trans  2017; 45(4): 905-11.
 [http://dx.doi.org/10.1042/BST20160466] [PMID: 28673937]

[4]
Bower JE, Greendale G, Crosswell AD, et al. Yoga reduces inflammatory signaling in fatigued breast cancer survivors: A randomized controlled trial. Psychoneuroendocrinology  2014; 43: 20-9.
 [http://dx.doi.org/10.1016/j.psyneuen.2014.01.019] [PMID: 24703167]

[5]
Khosravi N, Stoner L, Farajivafa V, Hanson ED. Exercise training, circulating cytokine levels and immune function in cancer survivors: A meta-analysis. Brain Behav Immun  2019; 81: 92-104.
 [http://dx.doi.org/10.1016/j.bbi.2019.08.187] [PMID: 31454519]

[6]
Kruijsen-Jaarsma M, Révész D, Bierings MB, Buffart LM, Takken T. Effects of exercise on immune function in patients with cancer: A systematic review. Exerc Immunol Rev  2013; 19: 120-43.
 [PMID: 23977724]

[7]
Stoner L, Lucero AA, Palmer BR, Jones LM, Young JM, Faulkner J. Inflammatory biomarkers for predicting cardiovascular disease. Clin Biochem  2013; 46(15): 1353-71.
 [http://dx.doi.org/10.1016/j.clinbiochem.2013.05.070] [PMID: 23756129]

[8]
Singh N, Baby D, Rajguru J, Patil P, Thakkannavar S, Pujari V. Inflammation and cancer. Ann Afr Med  2019; 18(3): 121-6.
 [http://dx.doi.org/10.4103/aam.aam_56_18] [PMID: 31417011]

[9]
Murata M. Inflammation and cancer. Environ Health Prev Med  2018; 23(1): 50.
 [http://dx.doi.org/10.1186/s12199-018-0740-1] [PMID: 30340457]

[10]
Yao J, Caballero OL, Yung WKA, et al. Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.  Cancer Immunol Res  2014; 2(4): 371-9.
 [http://dx.doi.org/10.1158/2326-6066.CIR-13-0088] [PMID: 24764584]

[11]
Kartikasari AER, Huertas CS, Mitchell A, Plebanski M. Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. Front Oncol  2021; 11: 692142.
 [http://dx.doi.org/10.3389/fonc.2021.692142] [PMID: 34307156]

[12]
Stojkovic S, Kaun C, Heinz M, et al. Interleukin-33 induces urokinase in human endothelial cells-possible impact on angiogenesis. J Thromb Haemost  2014; 12(6): 948-57.
 [http://dx.doi.org/10.1111/jth.12581] [PMID: 24702774]

[13]
Voronov E, Carmi Y, Apte RN. The role IL-1 in tumor-mediated angiogenesis. Front Physiol  2014; 5: 114.
 [http://dx.doi.org/10.3389/fphys.2014.00114] [PMID: 24734023]

[14]
Watari K, Shibata T, Kawahara A, et al. Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages. PLoS One  2014; 9(6): e99568.
 [http://dx.doi.org/10.1371/journal.pone.0099568] [PMID: 24924428]

[15]
Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem  2013; 59(1): 85-93.
 [http://dx.doi.org/10.1373/clinchem.2012.185363] [PMID: 23193058]

[16]
Jiang X, Wang J, Deng X, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res  2020; 39(1): 204.
 [http://dx.doi.org/10.1186/s13046-020-01709-5] [PMID: 32993787]

[17]
Voronov E, Apte RN. Targeting the tumor microenvironment by intervention in interleukin-1 biology. Curr Pharm Des  2017; 23(32): 4893-905.
 [http://dx.doi.org/10.2174/1381612823666170613080919] [PMID: 28606052]

[18]
Gong Z, Ma J, Su H, et al. Interleukin-1 receptor antagonist inhibits angiogenesis in gastric cancer. Int J Clin Oncol  2018; 23(4): 659-70.
 [http://dx.doi.org/10.1007/s10147-018-1242-2] [PMID: 29344744]

[19]
Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev  2010; 29(2): 317-29.
 [http://dx.doi.org/10.1007/s10555-010-9229-0] [PMID: 20422276]

[20]
Bar D, Apte RN, Voronov E, Dinarello CA, Cohen S. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J  2004; 18(1): 161-3.
 [http://dx.doi.org/10.1096/fj.03-0483fje] [PMID: 14597552]

[21]
Slotwinski R, Olszewski WL, Slotkowski M, et al. Can the interleukin-1 receptor antagonist (IL-1ra) be a marker of anti-inflammatory response to enteral immunonutrition in malnourished patients after pancreaticoduodenectomy? JOP  2007; 8(6): 759-69.
 [PMID: 17993728]

[22]
Mokart D, Capo C, Blache JL, et al. Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer. Br J Surg  2002; 89(11): 1450-6.
 [http://dx.doi.org/10.1046/j.1365-2168.2002.02218.x] [PMID: 12390391]

[23]
van der Sijde F, Dik W, Mustafa D, Vietsch E, van Eijck C. Circulating cytokine levels as biomarkers for response to FOLFIRINOX chemotherapy in pancreatic cancer patients. HPB (Oxford)  2021; 23: S233-4.
 [http://dx.doi.org/10.1016/j.hpb.2020.11.586]

[24]
Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. OncoImmunology  2016; 5(6): e1163462.
 [http://dx.doi.org/10.1080/2162402X.2016.1163462] [PMID: 27471638]

[25]
Rosenberg SA. IL-2: The first effective immunotherapy for human cancer. J Immunol  2014; 192(12): 5451-8.
 [http://dx.doi.org/10.4049/jimmunol.1490019] [PMID: 24907378]

[26]
Gerber SA, Sorensen EW, Sedlacek AL, et al. Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology  2013; 138(3): 280-92.
 [http://dx.doi.org/10.1111/imm.12037] [PMID: 23198850]

[27]
Forones NM, Mandowsky SV, Lourenço LG. Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer. Hepatogastroenterology  2001; 48(40): 1199-201.
 [PMID: 11490833]

[28]
Nguyen LT, Saibil SD, Sotov V, et al. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Cancer Immunol Immunother  2019; 68(5): 773-85.
 [http://dx.doi.org/10.1007/s00262-019-02307-x] [PMID: 30747243]

[29]
Ackermann M, Haake K, Kempf H, et al. A 3D iPSC-differentiation model identifies interleukin-3 as a regulator of early human hematopoietic specification. Haematologica  2020; 106(5): 1354-67.
 [http://dx.doi.org/10.3324/haematol.2019.228064] [PMID: 32327499]

[30]
Hatfield KJ, Reikvam H, Bruserud Ø. Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells. Expert Opin Ther Targets  2014; 18(11): 1237-51.
 [http://dx.doi.org/10.1517/14728222.2014.957671] [PMID: 25200484]

[31]
Broughton SE, Dhagat U, Hercus TR, et al. The GM – CSF / IL-3 / IL-5 cytokine receptor family: From ligand recognition to initiation of signaling. Immunol Rev  2012; 250(1): 277-302.
 [http://dx.doi.org/10.1111/j.1600-065X.2012.01164.x] [PMID: 23046136]

[32]
Pate M, Damarla V, Chi DS, Negi S, Krishnaswamy G. Endothelial cell biology: Role in the inflammatory response. Adv Clin Chem  2010; 52: 109-30.
 [http://dx.doi.org/10.1016/S0065-2423(10)52004-3] [PMID: 21275341]

[33]
Bowers SLK, Kemp SS, Aguera KN, Koller GM, Forgy JC, Davis GE. Defining an upstream VEGF (vascular endothelial growth factor) priming signature for downstream factor-induced endothelial cell-pericyte tube network coassembly. Arterioscler Thromb Vasc Biol  2020; 40(12): 2891-909.
 [http://dx.doi.org/10.1161/ATVBAHA.120.314517] [PMID: 33086871]

[34]
Lopati T, Grange C, Cavallari C, et al. Targeting IL-3Rα on tumor-derived endothelial cells blunts metastatic spread of triple-negative breast cancer via extracellular vesicle reprogramming. Oncogene  2020; 9(10): 1-14.

[35]
Chen J, Gong C, Mao H, et al. E2F1/SP3/STAT6 axis is required for IL-4-induced epithelial-mesenchymal transition of colorectal cancer cells. Int J Oncol  2018; 53(2): 567-78.
 [http://dx.doi.org/10.3892/ijo.2018.4429] [PMID: 29901191]

[36]
Lin X, Wang S, Sun M, et al. miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2- like TAM polarization. J Hematol Oncol  2019; 12(1): 1-14.
 [PMID: 30606227]

[37]
Xu JY, Xiong YY, Tang RJ, et al. Interleukin-5-induced eosinophil population improves cardiac function after myocardial infarction. Cardiovasc Res  2022; 118(9): 2165-78.
 [http://dx.doi.org/10.1093/cvr/cvab237] [PMID: 34259869]

[38]
Gevaert P, Han JK, Smith SG, et al. The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol  2022; 12911(9): 1413-23.
 [http://dx.doi.org/10.1002/alr.22994]

[39]
Ikutani M, Yanagibashi T, Ogasawara M, et al. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol  2012; 188(2): 703-13.
 [http://dx.doi.org/10.4049/jimmunol.1101270] [PMID: 22174445]

[40]
Lee SJ, Lee EJ, Kim SK, et al. Identification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; The roles of IL-5, IL-20, and IL-28A. PLoS One  2012; 7(9): e40267.
 [http://dx.doi.org/10.1371/journal.pone.0040267] [PMID: 22962576]

[41]
Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol  2018; 10(2): a028415.
 [http://dx.doi.org/10.1101/cshperspect.a028415] [PMID: 28620096]

[42]
Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol  2015; 16(5): 448-57.
 [http://dx.doi.org/10.1038/ni.3153] [PMID: 25898198]

[43]
Atsumi T, Singh R, Sabharwal L, et al. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res  2014; 74(1): 8-14.
 [http://dx.doi.org/10.1158/0008-5472.CAN-13-2322] [PMID: 24362915]

[44]
Phesse TJ, Buchert M, Stuart E, et al. Partial inhibition of gp130- Jak-Stat3 signaling prevents Wnt-β-catenin-mediated intestinal tumor growth and regeneration. Sci Signal  2014; 7(345): ra92-2.
 [http://dx.doi.org/10.1126/scisignal.2005411] [PMID: 25270258]

[45]
Hu B, Elinav E, Huber S, et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc Natl Acad Sci USA  2013; 110(24): 9862-7.
 [http://dx.doi.org/10.1073/pnas.1307575110] [PMID: 23696660]

[46]
van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci (Lond)  2020; 134(16): 2091-115.
 [http://dx.doi.org/10.1042/CS20191211] [PMID: 32808663]

[47]
Caetano MS, Zhang H, Cumpian AM, et al. IL6 blockade reprograms the lung tumor microenvironment to limit the development and progression of K-ras–mutant lung cancer. Cancer Res  2016; 76(11): 3189-99.
 [http://dx.doi.org/10.1158/0008-5472.CAN-15-2840] [PMID: 27197187]

[48]
Xia L, Oyang L, Lin J, et al. The cancer metabolic reprogramming and immune response. Mol Cancer  2021; 20(1): 28.
 [http://dx.doi.org/10.1186/s12943-021-01316-8] [PMID: 33546704]

[49]
Huynh J, Chand A, Gough D, Ernst M. Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map. Nat Rev Cancer  2019; 19(2): 82-96.
 [http://dx.doi.org/10.1038/s41568-018-0090-8] [PMID: 30578415]

[50]
Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol  2011; 11(5): 330-42.
 [http://dx.doi.org/10.1038/nri2970] [PMID: 21508983]

[51]
Sportès C, Babb RR, Krumlauf MC, et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res  2010; 16(2): 727-35.
 [http://dx.doi.org/10.1158/1078-0432.CCR-09-1303] [PMID: 20068111]

[52]
Krzystek-Korpacka M, Zawadzki M, Neubauer K, et al. Elevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: Association with lymph node involvement and tumor location in the right colon. Cancer Immunol Immunother  2017; 66(2): 171-9.
 [http://dx.doi.org/10.1007/s00262-016-1933-3] [PMID: 27866242]

[53]
Todorović-Raković N, Milovanović J. Interleukin-8 in breast cancer progression. J Interferon Cytokine Res  2013; 33(10): 563-70.
 [http://dx.doi.org/10.1089/jir.2013.0023] [PMID: 23697558]

[54]
Green AR, Green VL, White MC, Speirs V. Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: Identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer  1997; 72(6): 937-41.
 [http://dx.doi.org/10.1002/(SICI)1097-0215(19970917)72:6<937::AID-IJC3>3.0.CO;2-Q] [PMID: 9378554]

[55]
De Larco JE, Wuertz BRK, Rosner KA, et al. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol  2001; 158(2): 639-46.
 [http://dx.doi.org/10.1016/S0002-9440(10)64005-9] [PMID: 11159200]

[56]
Lee JE, Zhu Z, Bai Q, et al. The role of interleukin-9 in cancer. Pathol Oncol Res  2020; 26(4): 2017-22.
 [http://dx.doi.org/10.1007/s12253-019-00665-6] [PMID: 31016637]

[57]
Ye ZJ, Zhou Q, Yin W, et al. Differentiation and immune regulation of IL-9-producing CD4+ T cells in malignant pleural effusion. Am J Respir Crit Care Med  2012; 186(11): 1168-79.
 [http://dx.doi.org/10.1164/rccm.201207-1307OC] [PMID: 23065014]

[58]
Chen N, Lv X, Li P, Lu K, Wang X. Role of high expression of IL-9 in prognosis of CLL. Int J Clin Exp Pathol  2014; 7(2): 716-21.
 [PMID: 24551294]

[59]
Wang J, Dong X, Zhu X, et al. Expression of interleukin-9 in colon cancer tissues and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao  2018; 38(8): 943-8.

[60]
Herbeuval JP, Lelievre E, Lambert C, Dy M, Genin C. Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol  2004; 172(7): 4630-6.
 [http://dx.doi.org/10.4049/jimmunol.172.7.4630] [PMID: 15034082]

[61]
Kovacs E. Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells? Leuk Res  2010; 34(7): 912-6.
 [http://dx.doi.org/10.1016/j.leukres.2009.08.012] [PMID: 19762082]

[62]
Jin JO, Han X, Yu Q. Interleukin-6 induces the generation of IL-10-producing Tr1 cells and suppresses autoimmune tissue inflammation. J Autoimmun  2013; 40: 28-44.
 [http://dx.doi.org/10.1016/j.jaut.2012.07.009] [PMID: 22921334]

[63]
Lippitz BE. Cytokine patterns in patients with cancer: A systematic review. Lancet Oncol  2013; 14(6): e218-28.
 [http://dx.doi.org/10.1016/S1470-2045(12)70582-X] [PMID: 23639322]

[64]
Putoczki TL, Ernst M. IL-11 signaling as a therapeutic target for cancer. Immunotherapy  2015; 7(4): 441-53.
 [http://dx.doi.org/10.2217/imt.15.17] [PMID: 25917632]

[65]
Robb L, Li R, Hartley L, Nandurkar HH, Koentgen F, Begley CG. Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. Nat Med  1998; 4(3): 303-8.
 [http://dx.doi.org/10.1038/nm0398-303] [PMID: 9500603]

[66]
Luis-Ravelo D, Antón I, Zandueta C, et al. A gene signature of bone metastatic colonization sensitizes for tumor-induced osteolysis and predicts survival in lung cancer. Oncogene  2014; 33(43): 5090-9.
 [http://dx.doi.org/10.1038/onc.2013.440] [PMID: 24166494]

[67]
Torroella-Kouri M, Keith J, Ivanova M, Lopez D. IL-11-induced reduction of C/EBP transcription factor binding may contribute to the IL-12 downregulation in tumor-bearing mice. Int J Oncol  2003; 22(2): 439-48.
 [http://dx.doi.org/10.3892/ijo.22.2.439] [PMID: 12527946]

[68]
Calon A, Espinet E, Palomo-Ponce S, et al. Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. Cancer Cell  2012; 22(5): 571-84.
 [http://dx.doi.org/10.1016/j.ccr.2012.08.013] [PMID: 23153532]

[69]
Trinchieri G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol  1995; 13(1): 251-76.
 [http://dx.doi.org/10.1146/annurev.iy.13.040195.001343] [PMID: 7612223]

[70]
Nguyen KG, Vrabel MR, Mantooth SM, et al. Localized interleukin-12 for cancer immunotherapy. Front Immunol  2020; 11: 575597.
 [http://dx.doi.org/10.3389/fimmu.2020.575597] [PMID: 33178203]

[71]
Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer  1994; 57(6): 920-5.
 [http://dx.doi.org/10.1002/ijc.2910570624] [PMID: 7515861]

[72]
Youssef SS, Mohammad MM, Ezz-El-Arab LR. Clinical significance of serum IL-12 level in patients with early breast carcinoma and its correlation with other tumor markers. Open Access Maced J Med Sci  2015; 3(4): 640-4.
 [http://dx.doi.org/10.3889/oamjms.2015.106] [PMID: 27275301]

[73]
Huang D, Sun L, Huang L, Chen Y. Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect. J Pers Med  2021; 11(2): 124.
 [http://dx.doi.org/10.3390/jpm11020124] [PMID: 33672813]

[74]
Fang J, Islam W, Maeda H. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv Drug Deliv Rev  2020; 157: 142-60.
 [http://dx.doi.org/10.1016/j.addr.2020.06.005] [PMID: 32553783]

[75]
Fu T, Lin Y, Zeng Q, Yao W, Han L. Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer. BMC Pulm Med  2020; 20(1): 175.
 [http://dx.doi.org/10.1186/s12890-020-01210-x] [PMID: 32552897]

[76]
Guo M, Wu F, Hu G, et al. Autologous tumor cell–derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion. Sci Transl Med  2019; 11(474): eaat5690.
 [http://dx.doi.org/10.1126/scitranslmed.aat5690] [PMID: 30626714]

[77]
Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: Molecular insights and therapeutic approaches. Cell Oncol (Dordr)  2020; 43(1): 1-18.
 [http://dx.doi.org/10.1007/s13402-019-00489-1] [PMID: 31900901]

[78]
Archer M, Dogra N, Kyprianou N. Inflammation as a driver of prostate cancer metastasis and therapeutic resistance. Cancers (Basel)  2020; 12(10): 2984.
 [http://dx.doi.org/10.3390/cancers12102984] [PMID: 33076397]

[79]
Buhrmann C, Yazdi M, Popper B, et al. Evidence that TNF-β induces proliferation in colorectal cancer cells and resveratrol can down-modulate it. Exp Biol Med (Maywood)  2019; 244(1): 1-12.
 [http://dx.doi.org/10.1177/1535370218824538] [PMID: 30661394]

[80]
Lai EW, Joshi BH, Martiniova L, et al. Overexpression of interleukin-13 receptor-α2 in neuroendocrine malignant pheochromocytoma: A novel target for receptor directed anti-cancer therapy. J Clin Endocrinol Metab  2009; 94(8): 2952-7.
 [http://dx.doi.org/10.1210/jc.2009-0309] [PMID: 19491224]

[81]
Chavey C, Bibeau F, Gourgou-Bourgade S, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res  2007; 9(1): R15.
 [http://dx.doi.org/10.1186/bcr1648] [PMID: 17261184]

[82]
Leonard WJ, Lin JX, O’Shea JJ. The γc family of cytokines: Basic biology to therapeutic ramifications. Immunity  2019; 50(4): 832-50.
 [http://dx.doi.org/10.1016/j.immuni.2019.03.028] [PMID: 30995502]

[83]
Waldmann TA. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: Implications for cancer therapy. Cancer Immunol Res  2015; 3(3): 219-27.
 [http://dx.doi.org/10.1158/2326-6066.CIR-15-0009] [PMID: 25736261]

[84]
Robinson TO, Schluns KS. The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol Lett  2017; 190: 159-68.
 [http://dx.doi.org/10.1016/j.imlet.2017.08.010] [PMID: 28823521]

[85]
Zhang M, Yao Z, Dubois S, Ju W, Müller JR, Waldmann TA. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci USA  2009; 106(18): 7513-8.
 [http://dx.doi.org/10.1073/pnas.0902637106] [PMID: 19383782]

[86]
Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): A novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev  1997; 8(3): 207-19.
 [http://dx.doi.org/10.1016/S1359-6101(97)00015-4] [PMID: 9462486]

[87]
Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer (Review). Oncol Lett  2011; 2(4): 583-9.
 [http://dx.doi.org/10.3892/ol.2011.300] [PMID: 22848232]

[88]
Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev  2009; 8(5): 379-83.
 [http://dx.doi.org/10.1016/j.autrev.2008.12.002] [PMID: 19105984]

[89]
Schulthess FT, Paroni F, Sauter NS, et al. CXCL10 impairs β cell function and viability in diabetes through TLR4 signaling. Cell Metab  2009; 9(2): 125-39.
 [http://dx.doi.org/10.1016/j.cmet.2009.01.003] [PMID: 19187771]

[90]
Qiao Y, Li J, Yuh C, et al. Chemokine regulation in temporomandibular joint disease: A comprehensive review. Genes (Basel)  2023; 14(2): 408.
 [http://dx.doi.org/10.3390/genes14020408] [PMID: 36833336]

[91]
Cui LY, Chu SF, Chen NH. The role of chemokines and chemokine receptors in multiple sclerosis. Int Immunopharmacol  2020; 83: 106314.
 [http://dx.doi.org/10.1016/j.intimp.2020.106314] [PMID: 32197226]

[92]
Lv M, Xiaoping X, Cai H, et al. Cytokines as prognstic tool in breast carcinoma. Front Biosci  2011; 16(1): 2515-26.
 [http://dx.doi.org/10.2741/3869] [PMID: 21622192]

[93]
Dehqanzada Z, Storrer C, Hueman M, et al. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex® technology. Oncol Rep  2007; 17(3): 687-94.
 [http://dx.doi.org/10.3892/or.17.3.687] [PMID: 17273752]

[94]
Li L, Chen L, Zhang W, et al. Serum cytokine profile in patients with breast cancer. Cytokine  2017; 89: 173-8.
 [http://dx.doi.org/10.1016/j.cyto.2015.12.017] [PMID: 26898119]

[95]
Yoshimura T. The chemokine MCP-1 (CCL2) in the host interaction with cancer: A foe or ally? Cell Mol Immunol  2018; 15(4): 335-45.
 [http://dx.doi.org/10.1038/cmi.2017.135] [PMID: 29375123]

[96]
Monti P, Leone BE, Marchesi F, et al. The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: Regulation of expression and potential mechanisms of antimalignant activity. Cancer Res  2003; 63(21): 7451-61.
 [PMID: 14612545]

[97]
Okada M, Saio M, Kito Y, et al. Tumor-associated macrophage/ microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. Int J Oncol  2009; 34(6): 1621-7.
 [PMID: 19424580]

[98]
Liu Y, Cai Y, Liu L, Wu Y, Xiong X. Crucial biological functions of CCL7 in cancer. PeerJ  2018; 6: e4928.
 [http://dx.doi.org/10.7717/peerj.4928] [PMID: 29915688]

[99]
Hu JY, Li GC, Wang WM, et al. Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis. World J Gastroenterol  2002; 8(6): 1067-72.
 [http://dx.doi.org/10.3748/wjg.v8.i6.1067] [PMID: 12439927]

[100]
Velasco-Velázquez M, Xolalpa W, Pestell RG. The potential to target CCL5/CCR5 in breast cancer. Expert Opin Ther Targets  2014; 18(11): 1265-75.
 [http://dx.doi.org/10.1517/14728222.2014.949238] [PMID: 25256399]

[101]
Zhou B, Sun C, Li N, et al. Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways. Int J Oncol  2016; 48(5): 2087-97.
 [http://dx.doi.org/10.3892/ijo.2016.3442] [PMID: 26983899]

[102]
Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer  2013; 13(12): 871-82.
 [http://dx.doi.org/10.1038/nrc3627] [PMID: 24263190]

[103]
Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions. Angiogenesis  2014; 17(3): 471-94.
 [http://dx.doi.org/10.1007/s10456-014-9420-y] [PMID: 24482243]

[104]
Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med  2011; 17(7): 347-62.
 [http://dx.doi.org/10.1016/j.molmed.2011.01.015] [PMID: 21481637]

[105]
Martins SF, Reis RM, Rodrigues AM, Baltazar F, Filho AL. Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World J Clin Oncol  2011; 2(6): 272-80.
 [http://dx.doi.org/10.5306/wjco.v2.i6.272] [PMID: 21773077]

[106]
Cooper AM, Khader SA. IL-12p40: An inherently agonistic cytokine. Trends Immunol  2007; 28(1): 33-8.
 [http://dx.doi.org/10.1016/j.it.2006.11.002] [PMID: 17126601]

[107]
Abdi K. IL-12: The role of p40 versus p75. Scand J Immunol  2002; 56(1): 1-11.
 [http://dx.doi.org/10.1046/j.1365-3083.2002.01101.x] [PMID: 12100467]

[108]
Zijlmans HJM A A, Punt S, Fleuren GJ, Trimbos JB, Kenter GG, Gorter A. Role of IL-12p40 in cervical carcinoma. Br J Cancer  2012; 107(12): 1956-62.
 [http://dx.doi.org/10.1038/bjc.2012.488] [PMID: 23099807]

[109]
Stanilov N, Miteva L, Jovchev J, Cirovski G, Stanilova S. The prognostic value of preoperative serum levels of IL-12p40 and IL-23 for survival of patients with colorectal cancer. Acta Pathol Microbiol Scand Suppl  2014; 122(12): 1223-9.
 [http://dx.doi.org/10.1111/apm.12288] [PMID: 24909386]

[110]
Liu YL, Tsung JH, Fang CP, et al. Genetic polymorphisms on OPRM1 involved in multiple responses of a methadone maintenance population: Relationships with insomnia, libido, smoking, and chemokines.  Neuropathol Drug Addict Subst Misuse  2016; 532-41.

[111]
Wiedemann GM, Knott MML, Vetter VK, et al. Cancer cell-derived IL-1α induces CCL22 and the recruitment of regulatory T cells. OncoImmunology  2016; 5(9): e1175794.
 [http://dx.doi.org/10.1080/2162402X.2016.1175794] [PMID: 27757295]

[112]
Nakanishi T, Imaizumi K, Hasegawa Y, et al. Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer. Cancer Immunol Immunother  2006; 55(11): 1320-9.
 [http://dx.doi.org/10.1007/s00262-006-0133-y] [PMID: 16453150]

[113]
Neuber B, Herth I, Tolliver C, et al. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma. J Immunol  2011; 187(2): 1047-56.
 [http://dx.doi.org/10.4049/jimmunol.1002460] [PMID: 21677134]

[114]
Heckel MC, Wolfson A, Slachta CA, et al. Human breast tumor cells express IL-10 and IL-12p40 transcripts and proteins, but do not produce IL-12p70. Cell Immunol  2011; 266(2): 143-53.
 [http://dx.doi.org/10.1016/j.cellimm.2010.09.010] [PMID: 21055733]

[115]
Li T, Liu M, Dai H, et al. Value of cytokine expression in early diagnosis and prognosis of tumor metastasis. J Oncol  2022; 2022: 1-9.
 [http://dx.doi.org/10.1155/2022/8112190] [PMID: 36157224]

[116]
Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal  2013; 11(1): 97.
 [http://dx.doi.org/10.1186/1478-811X-11-97] [PMID: 24359404]

[117]
Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev  2008; 22(10): 1276-312.
 [http://dx.doi.org/10.1101/gad.1653708] [PMID: 18483217]

[118]
Ishii Y, Hamashima T, Yamamoto S, Sasahara M. Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor. Pathol Int  2017; 67(5): 235-46.
 [http://dx.doi.org/10.1111/pin.12530] [PMID: 28393435]

[119]
Ehnman M, Östman A. Therapeutic targeting of platelet-derived growth factor receptors in solid tumors. Expert Opin Investig Drugs  2014; 23(2): 211-26.
 [http://dx.doi.org/10.1517/13543784.2014.847086] [PMID: 24206431]

[120]
Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med  2018; 62: 75-88.
 [http://dx.doi.org/10.1016/j.mam.2017.11.007] [PMID: 29137923]

[121]
Plantureux L, Mège D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis. Cancers (Basel)  2018; 10(11): 441.
 [http://dx.doi.org/10.3390/cancers10110441] [PMID: 30441823]

[122]
Ingersoll SB, Langer F, Walker JM, et al. Deficiencies in the CD40 and CD154 receptor-ligand system reduce experimental lung metastasis. Clin Exp Metastasis  2009; 26(7): 829-37.
 [http://dx.doi.org/10.1007/s10585-009-9282-7] [PMID: 19642003]

[123]
Angelou A, Antoniou E, Garmpis N, Damaskos C, Theocharis S, Margonis GA. The role of soluble CD40L ligand in human carcinogenesis. Anticancer Res  2018; 38(5): 3199-201.
 [PMID: 29715163]

[124]
Richmond J, Tuzova M, Cruikshank W, Center D. Regulation of cellular processes by interleukin-16 in homeostasis and cancer. J Cell Physiol  2014; 229(2): 139-47.
 [http://dx.doi.org/10.1002/jcp.24441] [PMID: 23893766]

[125]
Overgaard NH, Jung JW, Steptoe RJ, Wells JW. CD4+/CD8+ double-positive T cells: More than just a developmental stage? J Leukoc Biol  2015; 97(1): 31-8.
 [http://dx.doi.org/10.1189/jlb.1RU0814-382] [PMID: 25360000]

[126]
Akdis M, Aab A, Altunbulakli C, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol  2016; 138(4): 984-1010.
 [http://dx.doi.org/10.1016/j.jaci.2016.06.033] [PMID: 27577879]

[127]
Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumour stage and previous therapy. Biomed Pharmacother  2001; 55(2): 111-6.
 [http://dx.doi.org/10.1016/S0753-3322(00)00023-8] [PMID: 11293814]

[128]
Allegra A, Alonci A, Bellomo G, et al. Serum levels of Interleukin-16 in a multiple myeloma patient with cutaneous involvement. Int J Dermatol  2010; 49(4): 435-7.
 [http://dx.doi.org/10.1111/j.1365-4632.2010.04321.x] [PMID: 20465701]

[129]
Yellapa A, Bahr JM, Bitterman P, et al. Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogenesis in laying hen model of spontaneous ovarian cancer. Int J Gynecol Cancer  2012; 22(2): 199-207.
 [http://dx.doi.org/10.1097/IGC.0b013e318236a27b] [PMID: 22274315]

[130]
Chen WC, Lai YH, Chen HY, Guo HR, Su IJ, Chen HHW. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology  2013; 63(2): 225-33.
 [http://dx.doi.org/10.1111/his.12156] [PMID: 23738752]

[131]
Welte T, Zhang XH. Interleukin-17 could promote breast cancer progression at several stages of the disease. Mediators Inflamm  2015; 2015: 804347.
 [http://dx.doi.org/10.1155/2015/804347]

[132]
Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol  2011; 29(1): 71-109.
 [http://dx.doi.org/10.1146/annurev-immunol-031210-101312] [PMID: 21166540]

[133]
Hsing CH, Hsieh MY, Chen WY, Cheung So E, Cheng BC, Chang MS. Induction of interleukin-19 and interleukin-22 after cardiac surgery with cardiopulmonary bypass. Ann Thorac Surg  2006; 81(6): 2196-201.
 [http://dx.doi.org/10.1016/j.athoracsur.2006.01.092] [PMID: 16731153]

[134]
Bergmann CB, Beckmann N, Salyer CE, Hanschen M, Crisologo PA, Caldwell CC. Potential targets to mitigate trauma-or sepsis-induced immune suppression. Front Immunol  2021; 12: 622601.
 [http://dx.doi.org/10.3389/fimmu.2021.622601] [PMID: 33717127]

[135]
Parma A, Cometi L, Leone MC, Lepri G, Talarico R, Guiducci S. One year in review 2016: Spondyloarthritis. Clin Exp Rheumatol  2017; 35(1): 3-17.
 [PMID: 28150582]

[136]
Autieri MV. IL-19 and other IL-20 family member cytokines in vascular inflammatory diseases. Front Immunol  2018; 9: 700.
 [http://dx.doi.org/10.3389/fimmu.2018.00700] [PMID: 29681905]

[137]
Fujimoto Y, Kuramoto N, Yoneyama M, Azuma YT. Interleukin-19 as an immunoregulatory cytokine. Curr Mol Pharmacol  2020; 14(2): 191-9.
 [http://dx.doi.org/10.2174/1874467213666200424151528] [PMID: 32329704]

[138]
Bao L, Shi VY, Chan LS. IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro: Relevant in the pathogenesis of atopic dermatitis. Cytokine  2013; 61(2): 419-25.
 [http://dx.doi.org/10.1016/j.cyto.2012.10.031] [PMID: 23207180]

[139]
Hsing CH, Cheng HC, Hsu YH, et al. Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome. Clin Cancer Res  2012; 18(3): 713-25.
 [http://dx.doi.org/10.1158/1078-0432.CCR-11-1532] [PMID: 22186257]

[140]
Weng YH, Chen WY, Lin YL, Wang JY, Chang MS. Blocking IL-19 signaling ameliorates allergen-induced airway inflammation. Front Immunol  2019; 10: 968.
 [http://dx.doi.org/10.3389/fimmu.2019.00968] [PMID: 31114590]

[141]
Azuma YT, Nishiyama K. Interleukin-19 enhances cytokine production induced by lipopolysaccharide and inhibits cytokine production induced by polyI:C in BALB/c mice. J Vet Med Sci  2020; 82(7): 891-6.
 [http://dx.doi.org/10.1292/jvms.20-0137] [PMID: 32378521]

[142]
Bazid H, Marae A, Tayel N, et al. Interleukin19 gene polymorphism and its serum level in acne vulgaris patients. J Immunoassay Immunochem  2022; 43(1): 1951291.
 [http://dx.doi.org/10.1080/15321819.2021.1952425] [PMID: 34292139]

[143]
Hsing CH, Li HH, Hsu YH, et al. The distribution of interleukin-19 in healthy and neoplastic tissue. Cytokine  2008; 44(2): 221-8.
 [http://dx.doi.org/10.1016/j.cyto.2008.06.007] [PMID: 18809337]

[144]
Gallagher G. Interleukin-19: Multiple roles in immune regulation and disease. Cytokine Growth Factor Rev  2010; 21(5): 345-52.
 [http://dx.doi.org/10.1016/j.cytogfr.2010.08.005] [PMID: 20889366]

[145]
Niess JH, Hruz P, Kaymak T. The interleukin-20 cytokines in intestinal diseases. Front Immunol  2018; 9: 1373.
 [http://dx.doi.org/10.3389/fimmu.2018.01373] [PMID: 29967613]

[146]
Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol  2007; 178(4): 2229-40.
 [http://dx.doi.org/10.4049/jimmunol.178.4.2229] [PMID: 17277128]

[147]
Rutz S, Wang X, Ouyang W. The IL-20 subfamily of cytokines - from host defence to tissue homeostasis. Nat Rev Immunol  2014; 14(12): 783-95.
 [http://dx.doi.org/10.1038/nri3766] [PMID: 25421700]

[148]
Hsu YH, Chang MS. The therapeutic potential of anti-interleukin-20 monoclonal antibody. Cell Transplant  2014; 23(4-5): 631-9.
 [http://dx.doi.org/10.3727/096368914X678319] [PMID: 24816455]

[149]
Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: Mechanisms of bone loss. Breast Cancer Res  2010; 12(6): 215.
 [http://dx.doi.org/10.1186/bcr2781] [PMID: 21176175]

[150]
Hsu YH, Hsing CH, Li CF, et al. Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. J Immunol  2012; 188(4): 1981-91.
 [http://dx.doi.org/10.4049/jimmunol.1102843] [PMID: 22238453]

[151]
Li P, Leonard WJ. Chromatin accessibility and interactions in the transcriptional regulation of T cells. Front Immunol  2018; 9: 2738.
 [http://dx.doi.org/10.3389/fimmu.2018.02738] [PMID: 30524449]

[152]
Spolski R, Leonard WJ. Interleukin-21: A double-edged sword with therapeutic potential. Nat Rev Drug Discov  2014; 13(5): 379-95.
 [http://dx.doi.org/10.1038/nrd4296] [PMID: 24751819]

[153]
Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV. Interleukin 21: Combination strategies for cancer therapy. Nat Rev Drug Discov  2008; 7(3): 231-40.
 [http://dx.doi.org/10.1038/nrd2482] [PMID: 18259184]

[154]
Steele N, Anthony A, Saunders M, et al. A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. Br J Cancer  2012; 106(5): 793-8.
 [http://dx.doi.org/10.1038/bjc.2011.599] [PMID: 22315057]

[155]
Dumoutier L, Van Roost E, Ameye G, Michaux L, Renauld J-C. IL-TIF/IL-22: Genomic organization and mapping of the human and mouse genes. Genes Immun  2000; 1(8): 488-94.
 [http://dx.doi.org/10.1038/sj.gene.6363716] [PMID: 11197690]

[156]
Hrestak D, Matijašić M, Čipčić Paljetak H, Ledić Drvar D, Ljubojević Hadžavdić S, Perić M. Skin microbiota in atopic dermatitis. Int J Mol Sci  2022; 23(7): 3503.
 [http://dx.doi.org/10.3390/ijms23073503] [PMID: 35408862]

[157]
Harker JA, Lloyd CM. Overlapping and distinct features of viral and allergen immunity in the human lung. Immunity  2021; 54(4): 617-31.
 [http://dx.doi.org/10.1016/j.immuni.2021.03.010] [PMID: 33852829]

[158]
Glal D, Sudhakar JN, Lu HH, et al. ATF3 sustains IL-22-induced STAT3 phosphorylation to maintain mucosal immunity through inhibiting phosphatases. Front Immunol  2018; 9: 2522.
 [http://dx.doi.org/10.3389/fimmu.2018.02522] [PMID: 30455690]

[159]
Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: Vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med  2020; 46(6): 1105-8.
 [http://dx.doi.org/10.1007/s00134-020-06059-6] [PMID: 32347323]

[160]
Monastero RN, Pentyala S. Cytokines as biomarkers and their respective clinical cutoff levels. Int J Inflamm  2017; 2017: 1-11.
 [http://dx.doi.org/10.1155/2017/4309485] [PMID: 28487810]

[161]
Gulati K, Guhathakurta S, Joshi J, et al. Cytokines and their role in health and disease: A brief overview. MOJ Immunol  2016; 4(2): 00121.

[162]
Ma Y, Ren Y, Dai ZJ, Wu CJ, Ji YH, Xu J. IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients. Adv Clin Exp Med  2017; 26(3): 421-6.
 [http://dx.doi.org/10.17219/acem/62120] [PMID: 28791816]

[163]
Martínez-Reza I, Díaz L, García-Becerra R. Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer. J Biomed Sci  2017; 24(1): 90.
 [http://dx.doi.org/10.1186/s12929-017-0398-9] [PMID: 29202842]

[164]
Pradhan AK, Maji S, Bhoopathi P, et al. Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β. Proc Natl Acad Sci USA  2021; 118(21): e2103180118.
 [http://dx.doi.org/10.1073/pnas.2103180118] [PMID: 34016751]

[165]
Castaño Z, San Juan BP, Spiegel A, et al. IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. Nat Cell Biol  2018; 20(9): 1084-97.
 [http://dx.doi.org/10.1038/s41556-018-0173-5] [PMID: 30154549]

[166]
Mendoza-Rodríguez M, Arévalo Romero H, Fuentes-Pananá EM, Ayala-Sumuano JT, Meza I. IL-1β induces up-regulation of BIRC3, a gene involved in chemoresistance to doxorubicin in breast cancer cells. Cancer Lett  2017; 390: 39-44.
 [http://dx.doi.org/10.1016/j.canlet.2017.01.005] [PMID: 28093282]

[167]
Chen G, Liang Y, Guan X, et al. Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer. Am J Transl Res  2016; 8(5): 2255-64.
 [PMID: 27347332]

[168]
Yamaguchi M, Hashimoto K, Jijiwa M, Murata T. The inflammatory macrophages repress the growth of bone metastatic human prostate cancer cells via TNF-α and IL-6 signaling: Involvement of cell signaling regulator regucalcin. Cell Signal  2023; 107: 110663.
 [http://dx.doi.org/10.1016/j.cellsig.2023.110663] [PMID: 37001596]

[169]
Mu HQ, He YH, Wang SB, et al. MiR-130b/TNF-α/NF-κB/VEGFA loop inhibits prostate cancer angiogenesis. Clin Transl Oncol  2020; 22(1): 111-21.
 [http://dx.doi.org/10.1007/s12094-019-02217-5] [PMID: 31667686]

[170]
Méndez-Clemente A, Bravo-Cuellar A, González-Ochoa S, et al. Dual STAT-3 and IL-6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL-6/IL-6R/STAT-3 axis. Oncol Rep  2022; 48(2): 138.
 [http://dx.doi.org/10.3892/or.2022.8349] [PMID: 35703345]

[171]
Zhang J, Tang X, Jin Z, Zhang H. Interleukin-6 promotes cervical cancer development through janus kinase 2/signal transducer and activator of transcription 6 signaling pathway. J Biomater Tissue Eng  2021; 11(1): 76-83.
 [http://dx.doi.org/10.1166/jbt.2021.2526]

[172]
Zhou C, He X, Zeng Q, Zhang P, Wang C. CCDC7 activates interleukin-6 and vascular endothelial growth factor to promote proliferation via the JAK-STAT3 pathway in cervical cancer cells. OncoTargets Ther  2020; 13: 6229-44.
 [http://dx.doi.org/10.2147/OTT.S244663] [PMID: 32669853]

[173]
Yan X, Hui Y, Hua Y, et al. EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway. Biomed Pharmacother  2019; 109: 762-9.
 [http://dx.doi.org/10.1016/j.biopha.2018.10.125] [PMID: 30551529]

[174]
Pausch TM, Aue E, Wirsik NM, et al. Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes. Sci Rep  2020; 10(1): 5420.
 [http://dx.doi.org/10.1038/s41598-020-62416-x] [PMID: 32214219]

[175]
Vasiliades G, Kopanakis N, Vasiloglou M, et al. Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer. Int J Biol Markers  2012; 27(3): 186-94.
 [http://dx.doi.org/10.5301/JBM.2012.9348] [PMID: 22865301]

[176]
Shimizu M, Tanaka N. IL-8-induced O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem cell-like properties in colon and lung cancer cells. Oncogene  2019; 38(9): 1520-33.
 [http://dx.doi.org/10.1038/s41388-018-0533-4] [PMID: 30305725]

[177]
Liu YN, Chang TH, Tsai MF, et al. IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. Oncotarget  2015; 6(12): 10415-31.
 [http://dx.doi.org/10.18632/oncotarget.3389] [PMID: 25871388]

[178]
Gong K, Guo G, Gerber DE, et al. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest  2018; 128(6): 2500-18.
 [http://dx.doi.org/10.1172/JCI96148] [PMID: 29613856]

[179]
Heim L, Yang Z, Tausche P, et al. IL-9 producing tumor-infiltrating lymphocytes and Treg subsets drive immune escape of tumor cells in non-small cell lung cancer. Front Immunol  2022; 13: 859738.
 [http://dx.doi.org/10.3389/fimmu.2022.859738] [PMID: 35514957]

[180]
He J, Wang L, Zhang C, et al. Interleukin-9 promotes tumorigenesis through augmenting angiogenesis in non-small cell lung cancer. Int Immunopharmacol  2019; 75: 105766.
 [http://dx.doi.org/10.1016/j.intimp.2019.105766] [PMID: 31352324]

[181]
Xu W, Wu Y, Liu W, et al. Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma. Int J Biol Sci  2022; 18(13): 4884-900.
 [http://dx.doi.org/10.7150/ijbs.74647] [PMID: 35982911]

[182]
Wang D, Yang L, Yue D, et al. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion. Cancer Lett  2019; 452: 244-53.
 [http://dx.doi.org/10.1016/j.canlet.2019.03.040] [PMID: 30928379]

[183]
Jasrotia S, Gupta R, Sharma A, Halder A, Kumar L. Cytokine profile in multiple myeloma. Cytokine  2020; 136: 155271.
 [http://dx.doi.org/10.1016/j.cyto.2020.155271] [PMID: 32916474]

[184]
Jammal MP, Martins-Filho A, Silveira TP, Murta EF, Nomelin RS. Cytokines and prognostic factors in epithelial ovarian cancer. Clin Med Insights Oncol  2016; 10: 71-6.
 [http://dx.doi.org/10.4137/CMO.S38333]

[185]
Li J, Xu L, Run ZC, et al. Multiple cytokine profiling in serum for early detection of gastric cancer. World J Gastroenterol  2018; 24(21): 2269-78.
 [http://dx.doi.org/10.3748/wjg.v24.i21.2269] [PMID: 29881236]

[186]
Sánchez-Zauco N, Torres J, Gómez A, et al. Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: A controlled study. BMC Cancer  2017; 17(1): 1-10.
 [PMID: 28049525]

[187]
Zhao J, Mo H. The impact of different anesthesia methods on stress reaction and immune function of the patients with gastric cancer during peri-operative period. J Med Assoc Thai  2015; 98(6): 568-73.
 [PMID: 26219161]

[188]
Zhang X, Hu F, Li G, et al. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. Cell Death Dis  2018; 9(2): 25.
 [http://dx.doi.org/10.1038/s41419-017-0176-3] [PMID: 29348540]

[189]
Liu H, Ren G, Wang T, et al. Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial–mesenchymal transition. Carcinogenesis  2015; 36(4): 459-68.
 [http://dx.doi.org/10.1093/carcin/bgv017] [PMID: 25750173]

[190]
Wang J, Sun M, Zhao H, et al. IL-9 exerts antitumor effects in colon cancer and transforms the tumor microenvironment in vivo. Technol Cancer Res Treat  2019; 18
 [http://dx.doi.org/10.1177/1533033819857737] [PMID: 31242804]

[191]
Xing X, Gu X, Ma T, Ye H. Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer. Tumour Biol  2015; 36(3): 1773-80.
 [http://dx.doi.org/10.1007/s13277-014-2779-y] [PMID: 25371074]

[192]
Abbassy HA, Aboelwafa RA, Ghallab OM. Evaluation of interleukin-9 expression as a potential therapeutic target in chronic lymphocytic leukemia in a cohort of Egyptian patients. Indian J Hematol Blood Transfus  2017; 33(4): 477-82.
 [http://dx.doi.org/10.1007/s12288-017-0804-1] [PMID: 29075057]

[193]
Lee EJ, Lee SJ, Kim S, et al. Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-κB/AP-1 pathway: Involvement of the p21WAF1 expression. Cell Signal  2013; 25(10): 2025-38.
 [http://dx.doi.org/10.1016/j.cellsig.2013.06.004] [PMID: 23770289]

[194]
James N, Ozsoy M, Cruz PDL, Woodman M, Ribeiro J. 729 Immunologic tumor cell intrinsic effects of standard of care therapies for ovarian cancer. J Immunother Cancer  2021; 9(2) (Suppl. 2): A758.
 [http://dx.doi.org/10.1136/jitc-2021-SITC2021.729]

[195]
Rahbar A, Cederarv M, Wolmer-Solberg N, et al. Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients. OncoImmunology  2016; 5(2): e1075693.
 [http://dx.doi.org/10.1080/2162402X.2015.1075693] [PMID: 27057448]

[196]
Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev  2011; 111(10): 5922-43.
 [http://dx.doi.org/10.1021/cr100396c] [PMID: 21766791]

[197]
Bi Q, Wu JY, Qiu XM, Zhang JD, Sun ZJ, Wang W. Tumor-associated inflammation: The tumor-promoting immunity in the early stages of tumorigenesis. J Immunol Res  2022; 2022: 1-13.
 [http://dx.doi.org/10.1155/2022/3128933] [PMID: 35733919]

[198]
Fernandes JV, Cobucci RNO, Jatobá CAN, de Medeiros Fernandes TAA, de Azevedo JWV, de Araújo JMG. The role of the mediators of inflammation in cancer development. Pathol Oncol Res  2015; 21(3): 527-34.
 [http://dx.doi.org/10.1007/s12253-015-9913-z] [PMID: 25740073]

[199]
Singh S, Mehta N, Lilan J, Budhthoki MB, Chao F, Yong L. Initiative action of tumor-associated macrophage during tumor metastasis. Biochim Open  2017; 4: 8-18.
 [http://dx.doi.org/10.1016/j.biopen.2016.11.002] [PMID: 29450136]

[200]
Das D, Karthik N, Taneja R. Crosstalk between inflammatory signaling and methylation in cancer. Front Cell Dev Biol  2021; 9: 756458.
 [http://dx.doi.org/10.3389/fcell.2021.756458] [PMID: 34901003]

[201]
Sullivan R, Maresh G, Zhang X, et al. The emerging roles of extracellular vesicles as communication vehicles within the tumor microenvironment and beyond. Front Endocrinol (Lausanne)  2017; 8: 194.
 [http://dx.doi.org/10.3389/fendo.2017.00194] [PMID: 28848498]

[202]
Gentric G, Mieulet V, Mechta-Grigoriou F. Heterogeneity in cancer metabolism: New concepts in an old field. Antioxid Redox Signal  2017; 26(9): 462-85.
 [http://dx.doi.org/10.1089/ars.2016.6750] [PMID: 27228792]
Cite As
Current Pharmaceutical Design

Cytokines as Potential Therapeutic Targets and their Role in the Diagnosis and Prediction of Cancers

Abstract
